Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences is making strong and steady progress in its goal of improving healthcare by making ECGs more effective for early detection of heart disease through AI technology. The company has shown impressive expense control, has multiple revenue streams in place for its AI-enabled ECG platform, and is on track for FDA approval and significant revenues from the over 100 million ECG tests performed annually in the US. The key risks for the company include balancing its balance sheet/liquidity, navigating regulatory approvals, and obtaining suitable reimbursement, but overall its potential for success and high market demand make it an attractive investment opportunity.

Bears say

HeartSciences is experiencing significant operating expenses, with a current total of $2.1 million, and a predicted increase in the future due to equity financing. While the company reported a slight beat in Q2 FY26, their real strength lies in their key device submission and upgrade to their AI-ECG software platform, which could potentially drive long-term growth and profitability for the company. However, given the uncertain nature of the medical technology industry and the competitive landscape, a negative outlook is justified as it is unclear if the company will be able to successfully penetrate the market and generate significant revenues in the near future.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.